HOME >> BIOLOGY >> NEWS
Nuclear medicine imaging allows prediction of breast cancer patients' response to hormonal treatment

Innovative use of somatostatin receptor scintigraphy (SRS), a nuclear medicine imaging technique looking at how the body functions at the molecular level, may provide near immediate selection of breast cancer patients for endocrine therapy and offers a new tool in fighting the disease, according to a study published in the January Journal of Nuclear Medicine.

Breast cancer is the most common cancer among women and the second leading cause of cancer death in this country. About one in eight women will develop invasive breast cancer some time during her life, and more than 40,000 (1 in 33) of those die from the disease each year in the United States. Advanced or metastatic breast cancer patients receive either hormonal or chemotherapy treatment, depending on the hormone sensitivity of a woman's tumor. In some women, the female hormone estrogen promotes the growth of breast cancer cells. Endocrine or hormonal therapy removes the influence of estrogen on breast cancer cells, preventing the cancer cells from growing and spreading.

"Our technique allows a fast and accurate selection of breast cancer patients for hormonal treatment," explained Bieke Van Den Bossche, M.D., Ph.D., nuclear medicine department, Ghent University Hospital, Ghent, Belgium. "In routine practice, patients are assigned to hormonal treatment--or not--depending on the hormone receptor status of the primary tumor," said Van Den Bossche, co-author of "Early Prediction of Endocrine Therapy Effect in Advanced Breast Cancer Patients Using 99mTc-Depreotide Scintigraphy." She added, "With conventional imaging techniques, it takes at least three to six months to evaluate if the disease is regressing, stabilizing or progressing. Obviously, every day that a patient goes without efficient therapy is a day too many."

Hormonal treatment provides good results with minor side effects, but only patients who have tumors and metastases (spread) sensitive to hormones benefit from this type of t
'"/>

Contact: Maryann Verrillo
mverrillo@snm.org
703-708-9000
Society of Nuclear Medicine
19-Jan-2006


Page: 1 2 3

Related biology news :

1. Journal of Nuclear Medicines impact grows, remains consistently high over past 5 years
2. Depiction of findings selected as 2007 Image of the Year by Society for Nuclear Medicine
3. SNM recognizes R. Edward Coleman with 2007 Georg Charles de Hevesy Nuclear Pioneer Award
4. Journal of Nuclear Medicine releases new research faster
5. PET/CT in Cancer Patient Management examined in Journal of Nuclear Medicine Supplement
6. Nuclear medicine patients: No-alarm holiday travel tips
7. Society of Nuclear Medicine offers free access to Journal of Nuclear Medicine
8. Journal of Nuclear Medicine publishes NCI-sponsored guidelines for using FDG PET
9. SNM recognizes contributions of Walter Wolf with 2006 Georg Charles de Hevesy Nuclear Pioneer Award
10. SNM awards $25,000 Mallinckrodt Seed Grant in Molecular Imaging/Nuclear Medicine Research
11. Society of Nuclear Medicine commends FDA for release of new guidance documents

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/12/2020)... ... August 11, 2020 , ... Both ... NJ, have entered into license agreements with Housey Pharma’s HMI subsidiary to gain ... and J&J have annual Research and Development spending in excess of US $10 ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... company announced a new partnership with medical equipment manufacturer, Spectrum Solutions, to provide ... clients to strengthen their laboratory supply chain for more than 10 years. Early ...
(Date:7/18/2020)... ... ... Commercial launch readiness is a critical stage in a product life cycle. While ... global economic downturn will only increase price pressures overall for the industry. The era ... from every product launch is critical. However, history shows that only a third of ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 11, 2020 , ... The ... the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network (FSHD CTRN), with ... network is a consortium of academic research centers in the United States and ...
(Date:8/12/2020)... ... August 12, 2020 , ... Inc. magazine today revealed that ... FDA compliance consulting has been named on its annual Inc. 5000 list, the ... unique look at the most successful companies within the American economy’s most dynamic ...
(Date:8/3/2020)... ... 03, 2020 , ... ERT, the global leader ... been named one of the 100 most inspiring individuals in the life-sciences industry ... selected based on how they have inspired their colleagues and affected positive changes ...
(Date:7/31/2020)... ... ... R3 Stem Cell International is now offering patients the opportunity to receive four ... may choose which extremities they would like treated. , Several studies have shown just ... R3 International, umbilical cord tissue is obtained from a lab with a long history ...
Breaking Biology Technology:
Cached News: